Comparing the current results to its competitors, Intensity Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 19.72 %, recorded in the same quarter.
Intensity Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 47.73 %
Intensity Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape includes large companies such as Eli Lilly, GlaxoSmithKline, and Amgen, as well as smaller midsize organizations. Competitors develop products and therapies using similar scientific approaches, including intratumoral delivery or immune system activation. Specific companies developing immunotherapies targeting similar indications include Replimune Group, Inc., Amgen Inc., ImmVira Co., Ltd., IconOVir Bio, Inc., and FerGene, Inc. Potential competitors also include academic institutions, government agencies, and other public and private research organizations. Many competitors possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Mergers and acquisitions may concentrate resources among fewer competitors, while smaller or early-stage companies may also be significant competitors, particularly through collaborations with larger companies.
Publicly Traded Peers of Intensity Therapeutics Inc
Turnstone Biologics Corp Share Performance
-84.63%
One Year
Turnstone Biologics Corp
Profile
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Glaxosmithkline Plc's business model focuses on researching, developing, manufacturing, and marketing innovative healthcare products and medicines globally.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Sources:
Intensity Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intensity Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
